Difference between revisions of "STBT5:Volunteer Assignments and Opportunities"
Jump to navigation
Jump to search
[checked revision] | [checked revision] |
(5 intermediate revisions by 2 users not shown) | |||
Line 6: | Line 6: | ||
To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.<br /> | To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.<br /> | ||
+ | __TOC__ | ||
{| class="wikitable" style="margin:auto" | {| class="wikitable" style="margin:auto" | ||
|+<big>WHO Classification of Soft Tissue and Bone Tumours (5th edition) Content</big> | |+<big>WHO Classification of Soft Tissue and Bone Tumours (5th edition) Content</big> | ||
Line 16: | Line 17: | ||
!'''Date of Last Editor Review''' | !'''Date of Last Editor Review''' | ||
!'''Notes''' | !'''Notes''' | ||
− | |||
− | |||
− | |||
− | |||
− | |||
|- | |- | ||
− | |||
| | | | ||
− | + | ==== CHAPTER 2 (SOFT TISSUE TUMOURS) ==== | |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
---- | ---- | ||
Line 54: | Line 41: | ||
|[[STBT5:Lipoma|Lipoma]] | |[[STBT5:Lipoma|Lipoma]] | ||
|Disease | |Disease | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 70: | Line 52: | ||
|[[STBT5:Lipomatosis|Lipomatosis]] | |[[STBT5:Lipomatosis|Lipomatosis]] | ||
|Disease | |Disease | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 86: | Line 63: | ||
|[[STBT5:Lipomatosis_of_nerve|Lipomatosis of nerve]] | |[[STBT5:Lipomatosis_of_nerve|Lipomatosis of nerve]] | ||
|Disease | |Disease | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 102: | Line 74: | ||
|[[STBT5:Lipoblastoma_and_lipoblastomatosis|Lipoblastoma and lipoblastomatosis]] | |[[STBT5:Lipoblastoma_and_lipoblastomatosis|Lipoblastoma and lipoblastomatosis]] | ||
|Disease | |Disease | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 118: | Line 85: | ||
|[[STBT5:Angiolipoma_|Angiolipoma]] | |[[STBT5:Angiolipoma_|Angiolipoma]] | ||
|Disease | |Disease | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 134: | Line 96: | ||
|[[STBT5:Myolipoma_of_soft_tissue|Myolipoma of soft tissue]] | |[[STBT5:Myolipoma_of_soft_tissue|Myolipoma of soft tissue]] | ||
|Disease | |Disease | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 150: | Line 107: | ||
|[[STBT5:Chondroid_lipoma|Chondroid lipoma]] | |[[STBT5:Chondroid_lipoma|Chondroid lipoma]] | ||
|Disease | |Disease | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 166: | Line 118: | ||
|[[STBT5:Spindle_cell_lipoma_and_pleomorphic_lipoma|Spindle cell lipoma and pleomorphic lipoma]] | |[[STBT5:Spindle_cell_lipoma_and_pleomorphic_lipoma|Spindle cell lipoma and pleomorphic lipoma]] | ||
|Disease | |Disease | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 182: | Line 129: | ||
|[[STBT5:Hibernoma|Hibernoma]] | |[[STBT5:Hibernoma|Hibernoma]] | ||
|Disease | |Disease | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 198: | Line 140: | ||
|[[STBT5:Atypical_spindle_cell_/_pleomorphic_lipomatous_tumour|Atypical spindle cell / pleomorphic lipomatous tumour]] | |[[STBT5:Atypical_spindle_cell_/_pleomorphic_lipomatous_tumour|Atypical spindle cell / pleomorphic lipomatous tumour]] | ||
|Disease | |Disease | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 214: | Line 151: | ||
|[[STBT5:Atypical_lipomatous_tumour_/_well-differentiated_liposarcoma|Atypical lipomatous tumour / well-differentiated liposarcoma]] | |[[STBT5:Atypical_lipomatous_tumour_/_well-differentiated_liposarcoma|Atypical lipomatous tumour / well-differentiated liposarcoma]] | ||
|Disease | |Disease | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 235: | Line 167: | ||
| | | | ||
| | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[STBT5:Myxoid_liposarcoma|Myxoid liposarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 244: | Line 182: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Pleomorphic_liposarcoma_|Pleomorphic liposarcoma]] |
|Disease | |Disease | ||
| | | | ||
Line 254: | Line 192: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Myxoid_pleomorphic_liposarcoma|Myxoid pleomorphic liposarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 267: | Line 203: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Nodular_fasciitis|Nodular fasciitis]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 276: | Line 215: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Proliferative_fasciitis_and_proliferative_myositis|Proliferative fasciitis and proliferative myositis]] |
|Disease | |Disease | ||
| | | | ||
Line 286: | Line 225: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Myositis_ossificans_and_fibro-osseous_pseudotumour_of_digits|Myositis ossificans and fibro-osseous pseudotumour of digits]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 299: | Line 236: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Ischaemic_fasciitis|Ischaemic fasciitis]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 308: | Line 248: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Elastofibroma|Elastofibroma]] |
|Disease | |Disease | ||
| | | | ||
Line 315: | Line 255: | ||
| | | | ||
| | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[STBT5:Fibrous_hamartoma_of_infancy|Fibrous hamartoma of infancy]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 324: | Line 270: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Fibromatosis_colli|Fibromatosis colli]] |
|Disease | |Disease | ||
| | | | ||
Line 334: | Line 280: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Juvenile_hyaline_fibromatosis|Juvenile hyaline fibromatosis]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 347: | Line 291: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Inclusion_body_fibromatosis|Inclusion body fibromatosis]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 356: | Line 303: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Fibroma_of_tendon_sheath|Fibroma of tendon sheath]] |
|Disease | |Disease | ||
| | | | ||
Line 366: | Line 313: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Desmoplastic_fibroblastoma|Desmoplastic fibroblastoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 379: | Line 324: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Myofibroblastoma|Myofibroblastoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 388: | Line 336: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Calcifying_aponeurotic_fibroma|Calcifying aponeurotic fibroma]] |
|Disease | |Disease | ||
| | | | ||
Line 395: | Line 343: | ||
| | | | ||
| | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[STBT5:EWSR1-SMAD3-positive_fibroblastic_tumour_(emerging)|EWSR1-SMAD3-positive fibroblastic tumour (emerging)]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 404: | Line 358: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Angiomyofibroblastoma|Angiomyofibroblastoma]] |
|Disease | |Disease | ||
| | | | ||
Line 414: | Line 368: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Cellular_angiofibroma|Cellular angiofibroma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 427: | Line 379: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Angiofibroma_of_soft_tissue|Angiofibroma of soft tissue]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 436: | Line 391: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Nuchal-type_fibroma|Nuchal-type fibroma]] |
|Disease | |Disease | ||
| | | | ||
Line 446: | Line 401: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Acral_fibromyxoma|Acral fibromyxoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 459: | Line 412: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Gardner_fibroma|Gardner fibroma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 468: | Line 424: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Palmar_fibromatosis_and_plantar_fibromatosis|Palmar fibromatosis and plantar fibromatosis]] |
|Disease | |Disease | ||
| | | | ||
Line 475: | Line 431: | ||
| | | | ||
| | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[STBT5:Desmoid_fibromatosis|Desmoid fibromatosis]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 484: | Line 446: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Lipofibromatosis|Lipofibromatosis]] |
|Disease | |Disease | ||
| | | | ||
Line 494: | Line 456: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Giant_cell_fibroblastoma|Giant cell fibroblastoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 507: | Line 467: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Dermatofibrosarcoma_protuberans|Dermatofibrosarcoma protuberans]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 516: | Line 479: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Solitary_fibrous_tumour|Solitary fibrous tumour]] |
|Disease | |Disease | ||
+ | |Shashi Shetty and Reba Daniel (resident) | ||
+ | |2/21/2024 | ||
| | | | ||
+ | |PENDING | ||
| | | | ||
+ | |Katherine Geiersbach | ||
| | | | ||
+ | |Template added 2/21/2024 | ||
+ | |- | ||
+ | |[[STBT5:Inflammatory_myofibroblastic_tumour|Inflammatory myofibroblastic tumour]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 529: | Line 500: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Low-grade_myofibroblastic_sarcoma|Low-grade myofibroblastic sarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 539: | Line 510: | ||
| | | | ||
| | | | ||
+ | | | ||
+ | |- | ||
+ | |[[STBT5:Superficial_CD34-positive_fibroblastic_tumour|Superficial CD34-positive fibroblastic tumour]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 548: | Line 523: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Myxoinflammatory_fibroblastic_sarcoma|Myxoinflammatory fibroblastic sarcoma]] |
|Disease | |Disease | ||
| | | | ||
Line 558: | Line 533: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Infantile_fibrosarcoma|Infantile fibrosarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 571: | Line 544: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Adult_fibrosarcoma|Adult fibrosarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 580: | Line 556: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Myxofibrosarcoma|Myxofibrosarcoma]] |
|Disease | |Disease | ||
| | | | ||
Line 590: | Line 566: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Low-grade_fibromyxoid_sarcoma|Low-grade fibromyxoid sarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 595: | Line 574: | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Sclerosing_epithelioid_fibrosarcoma|Sclerosing epithelioid fibrosarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 609: | Line 588: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Tenosynovial_giant_cell_tumour|Tenosynovial giant cell tumour]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 619: | Line 598: | ||
| | | | ||
| | | | ||
+ | | | ||
+ | |- | ||
+ | |[[STBT5:Deep_fibrous_histiocytoma|Deep fibrous histiocytoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 628: | Line 611: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Plexiform_fibrohistiocytic_tumour|Plexiform fibrohistiocytic tumour]] |
|Disease | |Disease | ||
| | | | ||
Line 638: | Line 621: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Giant_cell_tumour_of_soft_tissue|Giant cell tumour of soft tissue]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 651: | Line 632: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Synovial_haemangioma|Synovial haemangioma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 660: | Line 644: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Intramuscular_angioma|Intramuscular angioma]] |
|Disease | |Disease | ||
| | | | ||
Line 670: | Line 654: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Arteriovenous_malformation/haemangioma|Arteriovenous malformation/haemangioma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 683: | Line 665: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Venous_haemangioma|Venous haemangioma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 692: | Line 677: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Anastomosing_haemangioma|Anastomosing haemangioma]] |
|Disease | |Disease | ||
− | |||
− | |||
| | | | ||
− | |||
| | | | ||
− | |||
| | | | ||
− | |||
| | | | ||
| | | | ||
Line 708: | Line 688: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Epithelioid_haemangioma|Epithelioid haemangioma]] |
|Disease | |Disease | ||
| | | | ||
Line 715: | Line 695: | ||
| | | | ||
| | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[STBT5:Lymphangioma_and_lymphangiomatosis|Lymphangioma and lymphangiomatosis]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 724: | Line 710: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Tufted_angioma_and_kaposiform_haemangioendothelioma|Tufted angioma and kaposiform haemangioendothelioma]] |
|Disease | |Disease | ||
| | | | ||
Line 731: | Line 717: | ||
| | | | ||
| | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[STBT5:Retiform_haemangioendothelioma|Retiform haemangioendothelioma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 740: | Line 732: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Papillary_intralymphatic_angioendothelioma|Papillary intralymphatic angioendothelioma]] |
|Disease | |Disease | ||
| | | | ||
Line 750: | Line 742: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Composite_haemangioendothelioma_|Composite haemangioendothelioma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 763: | Line 753: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Kaposi_sarcoma|Kaposi sarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 772: | Line 765: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Pseudomyogenic_haemangioendothelioma|Pseudomyogenic haemangioendothelioma]] |
|Disease | |Disease | ||
| | | | ||
Line 779: | Line 772: | ||
| | | | ||
| | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[STBT5:Epithelioid_haemangioendothelioma|Epithelioid haemangioendothelioma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 788: | Line 787: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Angiosarcoma|Angiosarcoma]] |
|Disease | |Disease | ||
| | | | ||
Line 798: | Line 797: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Glomus_tumour|Glomus tumour]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 811: | Line 808: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Myopericytoma,_including_myofibroma|Myopericytoma, including myofibroma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 820: | Line 820: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Angioleiomyoma|Angioleiomyoma]] |
|Disease | |Disease | ||
| | | | ||
Line 830: | Line 830: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Leiomyoma|Leiomyoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 843: | Line 841: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:EBV-associated_smooth_muscle_tumour|EBV-associated smooth muscle tumour]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 852: | Line 853: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Inflammatory_leiomyosarcoma|Inflammatory leiomyosarcoma]] |
|Disease | |Disease | ||
| | | | ||
Line 859: | Line 860: | ||
| | | | ||
| | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[STBT5:Leiomyosarcoma|Leiomyosarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 868: | Line 875: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Rhabdomyoma|Rhabdomyoma]] |
|Disease | |Disease | ||
| | | | ||
Line 878: | Line 885: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Embryonal_rhabdomyosarcoma|Embryonal rhabdomyosarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 891: | Line 896: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Alveolar_rhabdomyosarcoma|Alveolar rhabdomyosarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 900: | Line 908: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Pleomorphic_rhabdomyosarcoma|Pleomorphic rhabdomyosarcoma]] |
|Disease | |Disease | ||
| | | | ||
Line 910: | Line 918: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Spindle_cell_/_sclerosing_rhabdomyosarcoma|Spindle cell / sclerosing rhabdomyosarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 923: | Line 929: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Ectomesenchymoma|Ectomesenchymoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 932: | Line 941: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Gastrointestinal_stromal_tumour|Gastrointestinal stromal tumour]] |
|Disease | |Disease | ||
| | | | ||
Line 939: | Line 948: | ||
| | | | ||
| | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[STBT5:Soft_tissue_chondroma|Soft tissue chondroma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 948: | Line 963: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Extraskeletal_osteosarcoma|Extraskeletal osteosarcoma]] |
|Disease | |Disease | ||
| | | | ||
Line 958: | Line 973: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Schwannoma|Schwannoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 971: | Line 984: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Neurofibroma|Neurofibroma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 980: | Line 996: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Perineurioma|Perineurioma]] |
|Disease | |Disease | ||
| | | | ||
Line 990: | Line 1,006: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Granular_cell_tumour|Granular cell tumour]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,003: | Line 1,017: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Dermal_nerve_sheath_myxoma|Dermal nerve sheath myxoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,012: | Line 1,029: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Solitary_circumscribed_neuroma|Solitary circumscribed neuroma]] |
|Disease | |Disease | ||
| | | | ||
Line 1,019: | Line 1,036: | ||
| | | | ||
| | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[STBT5:Ectopic_meningioma_and_meningothelial_hamartoma|Ectopic meningioma and meningothelial hamartoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,028: | Line 1,051: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Benign_triton_tumour_/_neuromuscular_choristoma|Benign triton tumour / neuromuscular choristoma]] |
|Disease | |Disease | ||
| | | | ||
Line 1,038: | Line 1,061: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Hybrid_nerve_sheath_tumour|Hybrid nerve sheath tumour]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,051: | Line 1,072: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Malignant_peripheral_nerve_sheath_tumour|Malignant peripheral nerve sheath tumour]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,060: | Line 1,084: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Malignant_melanotic_nerve_sheath_tumour|Malignant melanotic nerve sheath tumour]] |
|Disease | |Disease | ||
| | | | ||
Line 1,070: | Line 1,094: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Intramuscular_myxoma|Intramuscular myxoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,083: | Line 1,105: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Juxta-articular_myxoma|Juxta-articular myxoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,092: | Line 1,117: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Deep_(aggressive)_angiomyxoma|Deep (aggressive) angiomyxoma]] |
|Disease | |Disease | ||
| | | | ||
Line 1,102: | Line 1,127: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Atypical_fibroxanthoma|Atypical fibroxanthoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,115: | Line 1,138: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Angiomatoid_fibrous_histiocytoma|Angiomatoid fibrous histiocytoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,124: | Line 1,150: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Ossifying_fibromyxoid_tumour|Ossifying fibromyxoid tumour]] |
|Disease | |Disease | ||
| | | | ||
Line 1,134: | Line 1,160: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Myoepithelioma,_myoepithelial_carcinoma,_and_mixed_tumour|Myoepithelioma, myoepithelial carcinoma, and mixed tumour]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,147: | Line 1,171: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Pleomorphic_hyalinizing_angiectatic_tumour_of_soft_parts|Pleomorphic hyalinizing angiectatic tumour of soft parts]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,156: | Line 1,183: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Haemosiderotic_fibrolipomatous_tumour|Haemosiderotic fibrolipomatous tumour]] |
|Disease | |Disease | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,172: | Line 1,194: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Phosphaturic_mesenchymal_tumour|Phosphaturic mesenchymal tumour]] |
|Disease | |Disease | ||
| | | | ||
Line 1,182: | Line 1,204: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:NTRK-rearranged_spindle_cell_neoplasm_(emerging)|NTRK-rearranged spindle cell neoplasm (emerging)]] | ||
+ | |Disease | ||
+ | |James Solomon, MD, PhD | ||
+ | |2/20/2022 | ||
| | | | ||
+ | |PENDING | ||
+ | | | ||
+ | |Alanna Church | ||
| | | | ||
| | | | ||
− | |||
− | |||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Synovial_sarcoma|Synovial sarcoma]] |
|Disease | |Disease | ||
| | | | ||
Line 1,198: | Line 1,226: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Epithelioid_sarcoma|Epithelioid sarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,211: | Line 1,237: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Alveolar_soft_part_sarcoma|Alveolar soft part sarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,220: | Line 1,249: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Clear_cell_sarcoma_of_soft_tissue|Clear cell sarcoma of soft tissue]] |
|Disease | |Disease | ||
| | | | ||
Line 1,230: | Line 1,259: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Extraskeletal_myxoid_chondrosarcoma_|Extraskeletal myxoid chondrosarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,243: | Line 1,270: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Desmoplastic_small_round_cell_tumour|Desmoplastic small round cell tumour]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,252: | Line 1,282: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Extrarenal_rhabdoid_tumour|Extrarenal rhabdoid tumour]] |
|Disease | |Disease | ||
| | | | ||
Line 1,259: | Line 1,289: | ||
| | | | ||
| | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[STBT5:PEComa|PEComa]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,268: | Line 1,304: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Intimal_sarcoma|Intimal sarcoma]] |
|Disease | |Disease | ||
| | | | ||
Line 1,278: | Line 1,314: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Undifferentiated_sarcoma|Undifferentiated sarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,283: | Line 1,322: | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
| | | | ||
+ | |- | ||
| | | | ||
+ | ==== CHAPTER 3 (UNDIFFERENTIATED SMALL ROUND CELL SARCOMAS OF BONE AND SOFT TISSUE) ==== | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Ewing_sarcoma|Ewing sarcoma]] |
|Disease | |Disease | ||
+ | |Sadeem Qdaisat | ||
+ | |10/1/23 | ||
| | | | ||
+ | |PENDING | ||
| | | | ||
+ | |Working with Eric McGinnis | ||
| | | | ||
− | | | + | |2021 template added |
− | | | + | |- |
+ | |[[STBT5:Round_cell_sarcoma_with_EWSR1-non-ETS_fusions|Round cell sarcoma with EWSR1-non-ETS fusions]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,316: | Line 1,369: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:CIC-rearranged_sarcoma|CIC-rearranged sarcoma]] |
|Disease | |Disease | ||
+ | |Ganesh Pandurang, MD | ||
+ | |2/28/24 | ||
| | | | ||
+ | |PENDING | ||
| | | | ||
+ | |Katherine Geiersbach | ||
| | | | ||
| | | | ||
− | | | + | |- |
+ | |[[STBT5:Sarcoma_with_BCOR_genetic_alterations|Sarcoma with BCOR genetic alterations]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,332: | Line 1,391: | ||
| | | | ||
|- | |- | ||
− | |||
− | |||
| | | | ||
+ | ==== CHAPTER 4 (BONE TUMOURS) ==== | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
+ | |- | ||
+ | |[[STBT5:Subungual_exostosis|Subungual exostosis]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,355: | Line 1,422: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Bizarre_parosteal_osteochondromatous_proliferation|Bizarre parosteal osteochondromatous proliferation]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,364: | Line 1,434: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Periosteal_chondroma|Periosteal chondroma]] |
|Disease | |Disease | ||
| | | | ||
Line 1,374: | Line 1,444: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Enchondroma|Enchondroma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,387: | Line 1,455: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Osteochondroma|Osteochondroma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,396: | Line 1,467: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Chondroblastoma|Chondroblastoma]] |
|Disease | |Disease | ||
| | | | ||
Line 1,406: | Line 1,477: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Chondromyxoid_fibroma|Chondromyxoid fibroma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,419: | Line 1,488: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Osteochondromyxoma|Osteochondromyxoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,428: | Line 1,500: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Synovial_chondromatosis|Synovial chondromatosis]] |
|Disease | |Disease | ||
| | | | ||
Line 1,438: | Line 1,510: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Central_atypical_cartilaginous_tumour_/_chondrosarcoma,_grade_1|Central atypical cartilaginous tumour / chondrosarcoma, grade 1]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,443: | Line 1,518: | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Secondary_peripheral_atypical_cartilaginous_tumour_/_chondrosarcoma,_grade_1|Secondary peripheral atypical cartilaginous tumour / chondrosarcoma, grade 1]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,456: | Line 1,531: | ||
| | | | ||
| | | | ||
+ | | | ||
+ | |- | ||
+ | |[[STBT5:Central_chondrosarcoma,_grades_2_and_3|Central chondrosarcoma, grades 2 and 3]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,467: | Line 1,543: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Secondary_peripheral_chondrosarcoma,_grades_2_and_3|Secondary peripheral chondrosarcoma, grades 2 and 3]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,476: | Line 1,555: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Periosteal_chondrosarcoma|Periosteal chondrosarcoma]] |
|Disease | |Disease | ||
| | | | ||
Line 1,486: | Line 1,565: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Clear_cell_chondrosarcoma|Clear cell chondrosarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,499: | Line 1,576: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Mesenchymal_chondrosarcoma|Mesenchymal chondrosarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,508: | Line 1,588: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Dedifferentiated_chondrosarcoma_|Dedifferentiated chondrosarcoma]] |
|Disease | |Disease | ||
| | | | ||
Line 1,518: | Line 1,598: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Osteoma|Osteoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,523: | Line 1,606: | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Osteoid_osteoma_|Osteoid osteoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,536: | Line 1,619: | ||
| | | | ||
| | | | ||
+ | | | ||
+ | |- | ||
+ | |[[STBT5:Osteoblastoma_|Osteoblastoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,547: | Line 1,631: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Low-grade_central_osteosarcoma|Low-grade central osteosarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,556: | Line 1,643: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Osteosarcoma|Osteosarcoma]] |
|Disease | |Disease | ||
| | | | ||
Line 1,566: | Line 1,653: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Parosteal_osteosarcoma_|Parosteal osteosarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,579: | Line 1,664: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Periosteal_osteosarcoma_|Periosteal osteosarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,588: | Line 1,676: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:High-grade_surface_osteosarcoma|High-grade surface osteosarcoma]] |
|Disease | |Disease | ||
| | | | ||
Line 1,598: | Line 1,686: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Secondary_osteosarcoma|Secondary osteosarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,603: | Line 1,694: | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Desmoplastic_fibroma_of_bone|Desmoplastic fibroma of bone]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,616: | Line 1,707: | ||
| | | | ||
| | | | ||
+ | | | ||
+ | |- | ||
+ | |[[STBT5:Fibrosarcoma_of_bone|Fibrosarcoma of bone]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,627: | Line 1,719: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Haemangioma_of_bone|Haemangioma of bone]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,636: | Line 1,731: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Epithelioid_haemangioma_of_bone|Epithelioid haemangioma of bone]] |
|Disease | |Disease | ||
| | | | ||
Line 1,646: | Line 1,741: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Epithelioid_haemangioendothelioma_of_bone|Epithelioid haemangioendothelioma of bone]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,659: | Line 1,752: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Angiosarcoma_of_bone|Angiosarcoma of bone]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,668: | Line 1,764: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Aneurysmal_bone_cyst|Aneurysmal bone cyst]] |
|Disease | |Disease | ||
| | | | ||
Line 1,678: | Line 1,774: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Giant_cell_tumour_of_bone_|Giant cell tumour of bone]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,683: | Line 1,782: | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Non-ossifying_fibroma|Non-ossifying fibroma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,696: | Line 1,795: | ||
| | | | ||
| | | | ||
+ | | | ||
+ | |- | ||
+ | |[[STBT5:Benign_notochordal_cell_tumour_|Benign notochordal cell tumour]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,707: | Line 1,807: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Conventional_chordoma|Conventional chordoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,716: | Line 1,819: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Dedifferentiated_chordoma|Dedifferentiated chordoma]] |
|Disease | |Disease | ||
| | | | ||
Line 1,726: | Line 1,829: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Poorly_differentiated_chordoma|Poorly differentiated chordoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,739: | Line 1,840: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Chondromesenchymal_hamartoma_of_chest_wall|Chondromesenchymal hamartoma of chest wall]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,748: | Line 1,852: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Osteofibrous_dysplasia_|Osteofibrous dysplasia]] |
|Disease | |Disease | ||
− | |||
− | |||
| | | | ||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,764: | Line 1,863: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Adamantinoma_of_long_bones|Adamantinoma of long bones]] |
|Disease | |Disease | ||
| | | | ||
Line 1,771: | Line 1,870: | ||
| | | | ||
| | | | ||
+ | | | ||
+ | | | ||
+ | | | ||
+ | |- | ||
+ | |[[STBT5:Simple_bone_cyst|Simple bone cyst]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,780: | Line 1,885: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Fibrocartilaginous_mesenchymoma|Fibrocartilaginous mesenchymoma]] |
|Disease | |Disease | ||
| | | | ||
Line 1,790: | Line 1,895: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Fibrous_dysplasia|Fibrous dysplasia]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,803: | Line 1,906: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Lipoma_and_hibernoma_of_bone|Lipoma and hibernoma of bone]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,812: | Line 1,918: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Leiomyosarcoma_of_bone|Leiomyosarcoma of bone]] |
|Disease | |Disease | ||
| | | | ||
Line 1,822: | Line 1,928: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Undifferentiated_pleomorphic_sarcoma|Undifferentiated pleomorphic sarcoma]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,835: | Line 1,939: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Bone_metastases|Bone metastases]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,844: | Line 1,951: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Solitary_plasmacytoma_of_bone|Solitary plasmacytoma of bone]] |
|Disease | |Disease | ||
| | | | ||
Line 1,854: | Line 1,961: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Primary_non-Hodgkin_lymphoma_of_bone|Primary non-Hodgkin lymphoma of bone]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 1,867: | Line 1,972: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Langerhans_cell_histiocytosis_|Langerhans cell histiocytosis]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,876: | Line 1,984: | ||
| | | | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Erdheim-Chester_disease_|Erdheim-Chester disease]] |
|Disease | |Disease | ||
| | | | ||
Line 1,886: | Line 1,994: | ||
| | | | ||
| | | | ||
+ | |- | ||
+ | |[[STBT5:Rosai-Dorfman_disease|Rosai-Dorfman disease]] | ||
+ | |Disease | ||
| | | | ||
| | | | ||
Line 1,891: | Line 2,002: | ||
| | | | ||
| | | | ||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
| | | | ||
+ | |- | ||
| | | | ||
+ | ==== CHAPTER 5 (GENETIC TUMOUR SYNDROMES OF SOFT TISSUE AND BONE) ==== | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
| | | | ||
+ | ---- | ||
|- | |- | ||
− | |[[STBT5: | + | |[[STBT5:Enchondromatosis|Enchondromatosis]] |
|Disease | |Disease | ||
| | | | ||
Line 1,918: | Line 2,037: | ||
| | | | ||
| | | | ||
− | + | |- | |
− | + | |[[STBT5:Li-Fraumeni_syndrome|Li-Fraumeni syndrome]] | |
− | + | |Disease | |
− | + | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] | |
− | + | |N/A | |
− | + | |N/A | |
− | + | |N/A | |
− | + | |N/A | |
− | + | |N/A | |
− | + | |N/A | |
− | + | |N/A | |
− | + | |- | |
− | + | |[[STBT5:McCune-Albright_syndrome|McCune-Albright syndrome]] | |
− | + | |Disease | |
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |- | ||
− | |[[STBT5: | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |Disease | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |[[ | ||
− | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | | | ||
− | | | ||
− | | | ||
− | | | ||
− | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | | | ||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |||
− | |- | ||
− | |[[STBT5:McCune-Albright_syndrome|McCune-Albright syndrome]] | ||
− | |Disease | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 2,992: | Line 2,062: | ||
|[[STBT5:Multiple_osteochondromas|Multiple osteochondromas]] | |[[STBT5:Multiple_osteochondromas|Multiple osteochondromas]] | ||
|Disease | |Disease | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 3,008: | Line 2,073: | ||
|[[STBT5:Neurofibromatosis_type_1|Neurofibromatosis type 1]] | |[[STBT5:Neurofibromatosis_type_1|Neurofibromatosis type 1]] | ||
|Disease | |Disease | ||
− | | | + | |[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]] |
− | + | |N/A | |
− | + | |N/A | |
− | + | |N/A | |
− | + | |N/A | |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | + | |N/A |
− | | | ||
− | | | ||
− | | | ||
− | | | ||
− | | | ||
|- | |- | ||
|[[STBT5:Rothmund-Thomson_syndrome|Rothmund-Thomson syndrome]] | |[[STBT5:Rothmund-Thomson_syndrome|Rothmund-Thomson syndrome]] | ||
|Disease | |Disease | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | | ||
Line 3,040: | Line 2,095: | ||
|[[STBT5:Werner_syndrome|Werner syndrome]] | |[[STBT5:Werner_syndrome|Werner syndrome]] | ||
|Disease | |Disease | ||
− | |||
− | |||
− | |||
− | |||
− | |||
| | | | ||
| | | |
Latest revision as of 13:47, 10 September 2024
Welcome!
For assignments, please see the "Author" column below (highlighted blue).
If empty (no name is present), please volunteer to create content for that disease!
To volunteer, please [Contact us] with your page of interest.